|
|
Volumn 321, Issue 2, 2019, Pages 145-146
|
|
Challenges of Non-Intention-to-Treat Analyses
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
HYPOCHOLESTEROLEMIC AGENT;
PLACEBO;
ROFECOXIB;
SAXAGLIPTIN;
SULFINPYRAZONE;
TOLVAPTAN;
ACUTE HEART FAILURE;
ALL CAUSE MORTALITY;
DATA ANALYSIS;
DIABETES MELLITUS;
FOLLOW UP;
HEART INFARCTION;
HUMAN;
INFORMATION PROCESSING;
INTENTION TO TREAT ANALYSIS;
ISCHEMIC HEART DISEASE;
MALIGNANT NEOPLASM;
METHODOLOGY;
OUTCOME ASSESSMENT;
PATIENT COMPLIANCE;
PREDICTION;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL (TOPIC);
SHORT SURVEY;
STATISTICAL ANALYSIS;
SYSTEMATIC ERROR;
TREATMENT OUTCOME;
DATA INTERPRETATION, STATISTICAL;
HUMANS;
INTENTION TO TREAT ANALYSIS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
|
|
EID: 85058517468
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2018.19192 Document Type: Short Survey |
|
Times cited : (39)
|
|
References (8)
|
